Delving into the Latest Updates on Shanghai Haiyan Pharmaceutical Technology Co Ltd with Synapse

Overview

Basic Info

Introduction

Established in May 2011, Shanghai Haiyan Pharmaceutical Technology Co., Ltd. operates from Zhangjiang Pharma Valley in the Pudong New Area of Shanghai. As a wholly-owned subsidiary of the Yangtze River Pharmaceutical Group, the company dedicates its efforts to the research and development of Class 1 innovative chemical drugs. Its focus encompasses the advancement of treatments in areas such as oncology, neurology, immunology, and cardiology.

Tags

Neoplasms

Nervous System Diseases

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	5

Top 5 Target	Count

EGFR(Epidermal growth factor receptor erbB1)	1
BTK(Tyrosine-protein kinase BTK)	1
μ opioid receptor(Mu opioid receptor)	1
A2aR x A2bR	1

Primary objective: To evaluate the pharmacodynamic interaction between YZJ-1139 tablets and escitalopram oxalate tablets in healthy subjects; Secondary objective: To evaluate the pharmacokinetic interaction between YZJ-1139 tablets and escitalopram oxalate tablets in healthy subjects; To observe the safety of taking YZJ-1139 tablets and escitalopram oxalate tablets together.

Start Date26 Aug 2024

Sponsor / Collaborator

Yangtze River Pharmacy Group Jiangsu Haici Biological Pharmacy

[+2]

CTR20242889 / Active, not recruitingPhase 1

YZJ-1139片与替格瑞洛片的药物相互作用研究

[Translation] Study on drug interaction between YZJ-1139 tablets and ticagrelor tablets

主要目的：在健康受试者中评价替格瑞洛片对YZJ-1139药代动力学特征的影响；次要目的：在健康受试者中评价替格瑞洛片与YZJ-1139片合用的安全性。

[Translation]

Primary objective: To evaluate the effect of ticagrelor tablets on the pharmacokinetic characteristics of YZJ-1139 in healthy subjects; Secondary objective: To evaluate the safety of ticagrelor tablets combined with YZJ-1139 tablets in healthy subjects.

Start Date22 Aug 2024

Sponsor / Collaborator

Yangtze River Pharmacy Group Jiangsu Haici Biological Pharmacy

[+2]

CTR20241147 / RecruitingPhase 1

评价YZJ-1139片在重度肾功能不全患者与肾功能正常受试者中的药代动力学与安全性

[Translation] To evaluate the pharmacokinetics and safety of YZJ-1139 tablets in patients with severe renal insufficiency and subjects with normal renal function

1）评价YZJ-1139片在重度肾功能不全患者和肾功能正常受试者中的药代动力学； 2）评价YZJ-1139片在重度肾功能不全患者和肾功能正常受试者中的安全性。

[Translation]

1) To evaluate the pharmacokinetics of YZJ-1139 tablets in patients with severe renal insufficiency and subjects with normal renal function; 2) To evaluate the safety of YZJ-1139 tablets in patients with severe renal insufficiency and subjects with normal renal function.

Start Date03 Jun 2024

Sponsor / Collaborator

Yangtze River Pharmacy Group Jiangsu Haici Biological Pharmacy

[+2]

100 Clinical Results associated with Shanghai Haiyan Pharmaceutical Technology Co Ltd

Login to view more data

0 Patents (Medical) associated with Shanghai Haiyan Pharmaceutical Technology Co Ltd

Login to view more data

2

Literatures (Medical) associated with Shanghai Haiyan Pharmaceutical Technology Co Ltd

01 Nov 2021·AAPS PharmSciTechQ3 · MEDICINE

Design and Characterization of HY-038 Solid Dispersions via Spray Drying Technology: In Vitro and In Vivo Evaluations

Q3 · MEDICINE

Article

Author: Han, Limei ; Sha, Xianyi ; He, Wenxiu ; Lu, Enhao ; Jiang, Taotao ; Du, Shilin

The aim of this study was to prepare HY-038 solid dispersions (SDs) with single carrier at high drug loading and then forming a tablet to enhance solubility, dissolution, and bioavailability via spray drying technology. At the same time, we hope to develop a more convenient in vitro method to predict the absorption behavior of different formulations in vivo. Different solid dispersions, varying in drug/polymer ratios, were prepared. Infrared spectroscopy, differential scanning calorimetry, scanning electron microscope, and X-ray diffraction were used to perform solid-state characterizations of the pure drug and SDs. Contact angle of water, dissolution in pH = 6.8 phosphate buffer, and in vivo absorption in dogs were studied. As a result, solid-state characterization demonstrated the transformation of the crystalline HY-038 to an amorphous state in the solid dispersions, and the in vivo exposure followed with the trend of the dissolution curve combined with contact angle. Compared with the prototype formulation, the C_max and AUC_0-∞ of optimized formulation SD2 (HY-038-HPMCAS 3:1) increased by about 5 ~ 9 times at the same dose. More importantly, the SD2 formulation showed approximately linear increases in C_max and AUC_0-∞ as the dose increased from 50 to 100 mg, while the prototype formulation reached absorption saturation at 50 mg. SD2 (HY-038-HPMCAS 3:1) was selected as the best formulation for the downstream development.

01 Mar 2017·Bioorganic & Medicinal Chemistry LettersQ4 · MEDICINE

Discovery of novel substituted octahydropyrrolo[3,4- c ]pyrroles as dual orexin receptor antagonists for insomnia treatment

Q4 · MEDICINE

Article

Author: Zhang, Hongmei ; Shen, Liang ; Luo, Zhi ; He, Haiying ; Hu, Yi ; Li, Yufeng ; Chen, Yuan ; Lan, Jiong ; Wang, Yuhe ; Li, Jian ; Sun, Yu ; Shi, Weihua ; Liu, Xing ; Cao, Changqing ; Lv, Qiang ; Hou, Lijuan ; Xu, Qing ; Wu, Songliang ; Chen, Shuhui ; Liang, Wei

A series of octahydropyrrolo[3,4-c]pyrroles were synthesized and evaluated by orexin 1 and 2 receptor (OX_{1 & 2} R) antagonists assays. Compound 14l with potent OXR antagonist activity and suitable pharmacokinetic behavior was chosen to be investigated in an EEG study, which demonstrated effects of sleep promotion comparable to Suvorexant. Furthermore, the di-fluro substituted analogs exhibited reduced hERG inhibition while maintaining moderate potency.

100 Deals associated with Shanghai Haiyan Pharmaceutical Technology Co Ltd

Login to view more data

100 Translational Medicine associated with Shanghai Haiyan Pharmaceutical Technology Co Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

2

IND Approval

Phase 1 Clinical

3

1

Phase 2 Clinical

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

YZJ-4729 ( μ opioid receptor )	Analgesia More	Phase 2
YZJ-5053 ( A2aR x A2bR )	Advanced Malignant Solid Neoplasm More	Phase 1
YZJ-3058 ( BTK )	-	Phase 1
YZJ-1495	-	Phase 1
YZJ-6097	Chronic cough More	IND Approval